anti-EGFR, pAb

CHF 315.00
In stock
YIF-LF-PA0186100 µlCHF 315.00
More Information
Product Details
Synonyms ERBB; EGFR; EC=; Proto-Oncogene c-ErbB-1; Epidermal Growth Factor Receptor; Receptor Tyrosine-Protein Kinase ErbB-1
Product Type Polyclonal Antibody
Immunogen/Antigen Synthetic peptide.

Western Blot (1:5,000)

Crossreactivity Human
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

The epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase of the ErbB (also known as HER) family in which four members have been identified: EGFR (ErbB1), HER2/Neu (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). All four erbB receptors are composed of an extracellular ligand-binding region consisting of glycosylated domains, a transmembrane domain containing a single hydrophobic anchor sequence, an intracellular region containing the catalytic tyrosine kinase domain, and a carboxyl-terminal region containing several tyrosine residues that become phosphorylated after receptor activation. The epidermal growth factor receptor (EGFR) signaling pathway is one of the most important pathways that regulate growth, survival, proliferation, and differentiation in mammalian cells. EGFR and other members of the erbB family form either homodimers or heterodimers upon ligand binding, resulting in conformational changes that allow activation of protein kinases and transphosphorylation of key tyrosine residues within the carboxyl-terminal domain. After the induction of tyrosine phosphorylation, some signaling pathways appear to start with the recognition of the C-terminal phosphotyrosines by appropriate adaptor or signaling molecules. The aberrant activation of the EGFR leads to enhanced proliferation and other tumor-promoting activities. Several mechanisms lead to aberrant receptor activation, including receptor overexpression, gene amplification, activating mutations, overexpression of receptor ligands, and/or loss of their negative regulatory mechanisms. The epidermal growth factor receptor (EGFR) has been extensively investigated as a target for anti-neoplastic therapy. Anti-EGFR antibodies that interfere with ligand-dependent receptor activation have shown clinical activity in a variety of solid tumors. Receptor for EGF, but also for other members of the EGF family, as TGF-α, amphiregulin, βcellulin, heparin-binding EGF-like growth factor, GP30 and vaccinia virus growth factor. Is involved in the control of cell growth and differentiation. Phosphorylates MUC1 in breast cancer cells and increases the interaction of MUC1 with SRC and CTNNB1/β-catenin. Isoform 2 may act as an antagonist of EGF action.

Product References

1) Camp E.R. et al., (2005) Clin Cancer Res. 11:397-405. (General)
2) Baselga J and Arteaga C.L., (2005) J Clin Oncol. 23:2445-2459. (General)
3) Oda K. et al., (2005) Mol Syst Biol. 1-17. (General)
4) Jorissen R.N. et al., (2003) Exp Cell Res. 284:31-53. (General)
5) McInnes C and Sykes B.D., (1997) Biopolymer. 43:339-366. (General)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.